Top Markets
Coin of the day
Relmada Therapeutics, Inc. Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc.

RLMD
Rang în acțiuni #13828
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company... Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Preț acțiune
$4.36
Capitalizare de piață
$457.32M
Schimbare (1 zi)
0.69%
Schimbare (1 an)
289.29%
Țară
US
Tranzacționează Relmada Therapeutics, Inc. (RLMD)

Categorie

EPS pentru Relmada Therapeutics, Inc. (RLMD)
EPS la data de 2026 TTM: 0
Conform celor mai recente rapoarte financiare și prețului acțiunilor Relmada Therapeutics, Inc., EPS-ul actual al companiei (TTM) este 0. La sfârșitul anului 2026, compania avea un EPS de 0 egal cu EPS-ului din 2026, care a fost de 0.
Istoricul EPS pentru Relmada Therapeutics, Inc. din 2026 până în 2026
EPS la sfârșitul fiecărui an
An EPS Schimbă
Nu sunt suficiente date pentru perioada selectată.
EPS pentru companii similare sau concurente
Companie EPS Diferență EPS Țara
$17.32 -
US
$27.74 -
NL
$-5.29 -
AU
$-7.98 -
US
- -
CH